Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Digest.
Press releases published on March 24, 2025
Madfu Secures Sharia Certification for its BNPL Solution
EIN Presswire
·
March 24, 2025
Madfu earns Sharia certification from Shariyah Review Bureau for its BNPL solution, boosting trust and aligning with Saudi Arabia’s fintech vision. RIYADH, AR RIYAD, SAUDI ARABIA, March 24, 2025 /EINPresswire.com/ -- Riyadh – Madfu, a leading Saudi- …
Robi Forms Strategic Partnership with The Binary Holdings to Introduce Web3 Gamification for 40M+ Users in Bangladesh
EIN Presswire
·
March 24, 2025
The partnership will enable TBH to integrate gamification into Robi’s ecosystem, helping subscribers earn rewards through data usage and mobile interactions. DUBAI, DUBAI, UNITED ARAB EMIRATES, March 24, 2025 /EINPresswire.com/ -- The Binary Holdings ( …
Provadent: The Science-Backed Supplement for Stronger Teeth & Gums
GlobeNewswire
·
March 24, 2025
TALLMADGE, Ohio, March 24, 2025 (GLOBE NEWSWIRE) -- Lately, more people are grappling with dental health problems. Whether it's cavities, gum disease, or just a dull ache that won’t go away, these issues are hard to ignore. It's clear that keeping our …
ABS further Strengthens Leadership Team with Appointment of Matthieu Boutrolle as Chief Technology Officer
EIN Presswire
·
March 24, 2025
DUBAI, UNITED ARAB EMIRATES, March 24, 2025 /EINPresswire.com/ -- ABS (Agility Beyond Space), a leading global satellite operator, is pleased to announce the appointment of Matthieu Boutrolle as its new Chief Technology Officer (CTO). With an extensive …
YouYaa UAE Becomes Global HQ Amid Strategic Focus on Middle East and Asia Growth
EIN Presswire
·
March 24, 2025
The award-winning digital growth agency sharpens focus on emerging markets to drive greater impact for fintech, crypto, and Web3 brands. DUBAI, DUBAI, UNITED ARAB EMIRATES, March 24, 2025 /EINPresswire.com/ -- YouYaa, a leading digital growth agency …
Coinchange Introduces API for Fintechs and Exchanges to Enable Passive Crypto Income
GlobeNewswire
·
March 24, 2025
Dubai, UAE, March 24, 2025 (GLOBE NEWSWIRE) -- Coinchange has introduced its Earn API, enabling FinTech and crypto exchanges to offer passive income opportunities to their users through decentralized finance (DeFi) strategies. The API provides returns of …
ZOOZ Power’s Kinetic Power Booster Powers Ultra-Fast EV Charging at New York Power Authority Work Site in Upstate New York
GlobeNewswire
·
March 24, 2025
Tel-Aviv, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- ZOOZ Power (Nasdaq and TASE: ZOOZ), a leading provider of flywheel-based power boosters and energy management systems enabling ultra-fast EV charging solutions, is successfully operating its ZOOZTER™-100 …
Silynxcom Advances its Revolutionary In-Ear Communication Solution with Real-Time Vital Signs Monitoring
GlobeNewswire
·
March 24, 2025
New potentially life-saving solution aims to enhance combat communication and safety Netanya, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Silynxcom Ltd. (NYSE American: SYNX) (“Silynxcom” or the “Company”), a manufacturer and developer of ruggedized …
Cyabra Report Uncovers AI-Driven Disinformation Campaign Targeting Pope Francis, Featured in The New York Times
GlobeNewswire
·
March 24, 2025
Cyabra has entered into a business combination agreement with Trailblazer Merger Corp. (TBMC) New York, NY, March 24, 2025 (GLOBE NEWSWIRE) -- Cyabra Ltd., a leading AI platform for real-time disinformation detection, has released a new report uncovering …
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
GlobeNewswire
·
March 24, 2025
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a …
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
GlobeNewswire
·
March 24, 2025
CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of innovative …
Chain Reaction’s Disruptive ASIC Technologies Enable Innovations with Industry-Leading Customers and Partners for Next-Generation Bitcoin Mining
GlobeNewswire
·
March 24, 2025
SAN JOSE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Chain Reaction, a semiconductor leader in next-generation Bitcoin mining and privacy-enhancing technology for encrypted AI computing, announces the launch of its 3nm EL3CTRUM A31 ASIC targeting sub-10 J …
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models
GlobeNewswire
·
March 24, 2025
SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying …
Aura Minerals Announces Renewal of Normal Course Issuer Bid and Concurrent Buyback Program for Brazilian Depositary Receipts
GlobeNewswire
·
March 24, 2025
ROAD TOWN, British Virgin Islands, March 24, 2025 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (TSX: ORA) (B3: AURA33) (OTCQX: ORAAF) ("Aura Minerals" or the "Company") announces today that the Toronto Stock Exchange (the "TSX") has accepted the Company's notice …
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting
GlobeNewswire
·
March 24, 2025
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized …
WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation
GlobeNewswire
·
March 24, 2025
SAN JOSE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced its Aquablation …
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
GlobeNewswire
·
March 24, 2025
Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALS Clene planning to initiate the confirmatory Phase 3 RESTORE-ALS trial in subjects with ALS in mid-2025 Secured new $10.0 …
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions
GlobeNewswire
·
March 24, 2025
PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients …
American Tungsten Corp. Applauds U.S. Presidential Executive Order to Increase Domestic Critical Mineral Production
GlobeNewswire
·
March 24, 2025
Vancouver, BC, March 24, 2025 (GLOBE NEWSWIRE) -- American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) (“American Tungsten” or the “Company”) applauds U.S. President Donald Trump’s Executive Order seeking to bolster the production of domestic …
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
GlobeNewswire
·
March 24, 2025
– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to …